Kemper elects Teladoc Health CEO Jason Gorevic to board; director Storch to retire

KEMPER Corp

Jason Gorevic, CEO of Teladoc Health, elected to Kemper's board effective Feb 2, 2022.
Gorevic appointed to Risk and Human Resources & Compensation Committees.
David Storch will not stand for re-election; his term ends May 4, 2022.
Board expands to 12 directors, 10 of whom are independent.
Gorevic brings 25+ years healthcare experience; Storch served 12 years on the board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David P. Storch

Director

KMPR · KEMPER Corp

Filed: February 3, 2022, 6:59 PM ET

David P. Storch notified the Board that he will not stand for re-election at our 2022 Annual Meeting of Shareholders.

Appointed

Jason N. Gorevic

Director

KMPR · KEMPER Corp

Effective: 2022-02-02
Filed: February 3, 2022, 6:59 PM ET

the Board of Directors (“Board”) of Kemper Corporation (“Company”) elected Jason N. Gorevic to the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

David P. Storch departed as Director at KEMPER Corp.

Action: not stand for re-election
Role: Director

Exact text from the filing

David P. Storch notified the Board that he will not stand for re-election at our 2022 Annual Meeting of Shareholders.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason N. Gorevic was elected as Director at KEMPER Corp.

Action: elected
Role: Director

Exact text from the filing

the Board of Directors (“Board”) of Kemper Corporation (“Company”) elected Jason N. Gorevic to the Board

View on SEC.gov

KEMPER Corp filing history →

Source: SEC EDGAR

accession 0000860748-22-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.